Clinical comparability of marketed formulations of botulinum toxin
Identifieur interne : 003D72 ( Main/Exploration ); précédent : 003D71; suivant : 003D73Clinical comparability of marketed formulations of botulinum toxin
Auteurs : Cristina Sampaio [Portugal] ; João Costa [Portugal] ; Joaquim J. Ferreira [Portugal]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Blepharospasm (drug therapy), Bontoxilysin, Botulinum Toxins, Type A (therapeutic use), Chemistry, Pharmaceutical, Confidence Intervals, Dystonia (drug therapy), Female, Formulation, Humans, Injections, Intramuscular, Male, Meta-Analysis as Topic, Middle Aged, Nervous system diseases, Neuromuscular Agents (therapeutic use), Treatment Outcome, botulinum toxin, clinical comparability of formulations, patent, potency.
- MESH :
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- drug therapy : Blepharospasm, Dystonia.
- Aged, Chemistry, Pharmaceutical, Confidence Intervals, Female, Humans, Injections, Intramuscular, Male, Meta-Analysis as Topic, Middle Aged, Treatment Outcome.
Abstract
The majority of pharmaceutical products are patented in early phases of their discovery to preclude competition by similar products. Due to unusual circumstances (botulinum toxin is an unpatentable natural product and it is considered to be a biological weapon), technology know‐how for botulinum toxin production was classified rather then available in the scientific community. Botulinum toxin type A was marketed in two pharmaceutical distinct formulations from competitor companies. Serendipity proved that the two formulations were not equipotent in terms of mouse units. From a regulatory point of view, differences in potency of distinct formulations are not a matter of concern because each formulation is licensed based on its own set of data. As far as the data in each case is sufficient to prove that a particular formulation is safe and efficacious at its defined dosage, a license for use can be granted. On the other hand, generation of data on comparability is the only way that clinicians and managers can ascertain which product (formulation, serotype) is most cost–effectiveness and to determine whether there are relevant differences in their safety profiles. The results of the systematic review of head‐to‐head randomised trials comparing BOTOX to Dysport suggest that the two formulations are not bioequivalent whatever the dose relationship. Data on comparative immunogenicity are not available. The indirect comparison of the results obtained in randomised clinical trials comparing BOTOX to placebo and Dysport to placebo support that intrinsic differences are present in the two products. It is concluded that comparative economic evaluations of different botulinum toxin formulations should move away from cost‐minimization approaches based on the presumption of bioequivalence and move toward cost‐effectiveness or cost‐utility models. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20066
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000098
- to stream Istex, to step Curation: 000098
- to stream Istex, to step Checkpoint: 002753
- to stream PubMed, to step Corpus: 003502
- to stream PubMed, to step Curation: 003502
- to stream PubMed, to step Checkpoint: 003520
- to stream Ncbi, to step Merge: 000D82
- to stream Ncbi, to step Curation: 000D82
- to stream Ncbi, to step Checkpoint: 000D82
- to stream Main, to step Merge: 005730
- to stream PascalFrancis, to step Corpus: 002247
- to stream PascalFrancis, to step Curation: 000A74
- to stream PascalFrancis, to step Checkpoint: 002206
- to stream Main, to step Merge: 005A44
- to stream Main, to step Curation: 003D72
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical comparability of marketed formulations of botulinum toxin</title>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
<author><name sortKey="Costa, Joao" sort="Costa, Joao" uniqKey="Costa J" first="João" last="Costa">João Costa</name>
</author>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BE98F5B1D74E9FE4010EC2A70B7370914ADDBD5C</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20066</idno>
<idno type="url">https://api.istex.fr/document/BE98F5B1D74E9FE4010EC2A70B7370914ADDBD5C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000098</idno>
<idno type="wicri:Area/Istex/Curation">000098</idno>
<idno type="wicri:Area/Istex/Checkpoint">002753</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Sampaio C:clinical:comparability:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15027065</idno>
<idno type="wicri:Area/PubMed/Corpus">003502</idno>
<idno type="wicri:Area/PubMed/Curation">003502</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003520</idno>
<idno type="wicri:Area/Ncbi/Merge">000D82</idno>
<idno type="wicri:Area/Ncbi/Curation">000D82</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D82</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Sampaio C:clinical:comparability:of</idno>
<idno type="wicri:Area/Main/Merge">005730</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0228361</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002247</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A74</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002206</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Sampaio C:clinical:comparability:of</idno>
<idno type="wicri:Area/Main/Merge">005A44</idno>
<idno type="wicri:Area/Main/Curation">003D72</idno>
<idno type="wicri:Area/Main/Exploration">003D72</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical comparability of marketed formulations of botulinum toxin</title>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinical Research Unit, Institute of Molecular Medicine, University of Lisbon</wicri:regionArea>
<wicri:noRegion>University of Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Costa, Joao" sort="Costa, Joao" uniqKey="Costa J" first="João" last="Costa">João Costa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinical Research Unit, Institute of Molecular Medicine, University of Lisbon</wicri:regionArea>
<wicri:noRegion>University of Lisbon</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurology Department, Hospital de Santa Maria, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinical Research Unit, Institute of Molecular Medicine, University of Lisbon</wicri:regionArea>
<wicri:noRegion>University of Lisbon</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-03">2004-03</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">S8</biblScope>
<biblScope unit="page" from="S129">S129</biblScope>
<biblScope unit="page" to="S136">S136</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">BE98F5B1D74E9FE4010EC2A70B7370914ADDBD5C</idno>
<idno type="DOI">10.1002/mds.20066</idno>
<idno type="ArticleID">MDS20066</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Blepharospasm (drug therapy)</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Chemistry, Pharmaceutical</term>
<term>Confidence Intervals</term>
<term>Dystonia (drug therapy)</term>
<term>Female</term>
<term>Formulation</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Male</term>
<term>Meta-Analysis as Topic</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Treatment Outcome</term>
<term>botulinum toxin</term>
<term>clinical comparability of formulations</term>
<term>patent</term>
<term>potency</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term>
<term>Dystonia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Chemistry, Pharmaceutical</term>
<term>Confidence Intervals</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Male</term>
<term>Meta-Analysis as Topic</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term>
<term>Formulation</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The majority of pharmaceutical products are patented in early phases of their discovery to preclude competition by similar products. Due to unusual circumstances (botulinum toxin is an unpatentable natural product and it is considered to be a biological weapon), technology know‐how for botulinum toxin production was classified rather then available in the scientific community. Botulinum toxin type A was marketed in two pharmaceutical distinct formulations from competitor companies. Serendipity proved that the two formulations were not equipotent in terms of mouse units. From a regulatory point of view, differences in potency of distinct formulations are not a matter of concern because each formulation is licensed based on its own set of data. As far as the data in each case is sufficient to prove that a particular formulation is safe and efficacious at its defined dosage, a license for use can be granted. On the other hand, generation of data on comparability is the only way that clinicians and managers can ascertain which product (formulation, serotype) is most cost–effectiveness and to determine whether there are relevant differences in their safety profiles. The results of the systematic review of head‐to‐head randomised trials comparing BOTOX to Dysport suggest that the two formulations are not bioequivalent whatever the dose relationship. Data on comparative immunogenicity are not available. The indirect comparison of the results obtained in randomised clinical trials comparing BOTOX to placebo and Dysport to placebo support that intrinsic differences are present in the two products. It is concluded that comparative economic evaluations of different botulinum toxin formulations should move away from cost‐minimization approaches based on the presumption of bioequivalence and move toward cost‐effectiveness or cost‐utility models. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Portugal</li>
</country>
</list>
<tree><country name="Portugal"><noRegion><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</noRegion>
<name sortKey="Costa, Joao" sort="Costa, Joao" uniqKey="Costa J" first="João" last="Costa">João Costa</name>
<name sortKey="Costa, Joao" sort="Costa, Joao" uniqKey="Costa J" first="João" last="Costa">João Costa</name>
<name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:BE98F5B1D74E9FE4010EC2A70B7370914ADDBD5C |texte= Clinical comparability of marketed formulations of botulinum toxin }}
This area was generated with Dilib version V0.6.23. |